CTSO vs. ZYXI, INGN, ELMD, PROF, LAKE, NVRO, SKIN, DRTS, CATX, and BWAY
Should you be buying Cytosorbents stock or one of its competitors? The main competitors of Cytosorbents include Zynex (ZYXI), Inogen (INGN), Electromed (ELMD), Profound Medical (PROF), Lakeland Industries (LAKE), Nevro (NVRO), Beauty Health (SKIN), Alpha Tau Medical (DRTS), Perspective Therapeutics (CATX), and BrainsWay (BWAY). These companies are all part of the "medical equipment" industry.
Cytosorbents vs.
Zynex (NASDAQ:ZYXI) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, community ranking, profitability, risk, media sentiment, earnings and valuation.
29.7% of Zynex shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 52.1% of Zynex shares are held by insiders. Comparatively, 6.6% of Cytosorbents shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Zynex has a net margin of 2.49% compared to Cytosorbents' net margin of -49.47%. Zynex's return on equity of 13.05% beat Cytosorbents' return on equity.
Cytosorbents received 411 more outperform votes than Zynex when rated by MarketBeat users. Likewise, 74.20% of users gave Cytosorbents an outperform vote while only 58.00% of users gave Zynex an outperform vote.
Zynex has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500.
Zynex presently has a consensus price target of $14.00, indicating a potential upside of 94.17%. Cytosorbents has a consensus price target of $4.67, indicating a potential upside of 353.07%. Given Cytosorbents' higher probable upside, analysts clearly believe Cytosorbents is more favorable than Zynex.
Zynex has higher revenue and earnings than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cytosorbents had 5 more articles in the media than Zynex. MarketBeat recorded 9 mentions for Cytosorbents and 4 mentions for Zynex. Zynex's average media sentiment score of 0.91 beat Cytosorbents' score of 0.44 indicating that Zynex is being referred to more favorably in the media.
Summary
Zynex beats Cytosorbents on 9 of the 17 factors compared between the two stocks.
Get Cytosorbents News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytosorbents Competitors List
Related Companies and Tools
This page (NASDAQ:CTSO) was last updated on 3/4/2025 by MarketBeat.com Staff
